Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Bioverativ Usa Inc. has 4 pending office actions in Biotechnology & Pharmaceuticals. Those matters involve 4 distinct examiners and 4 distinct art units, indicating that the pending work is distributed across both examining personnel and technical groups.
XIAO, YAN is the busiest examiner, with 1 pending matter. Counsel should review that matter separately because the available data does not indicate examiner concentration beyond that single assignment.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
| No statute on record | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| XIAO, YAN | 1 | 67.3% | +52.7% |
| KIM, YUNSOO | 1 | 66.0% | +34.0% |
| WEIDNER, ADAM M | 1 | 63.7% | +33.6% |
| HOWARD, ZACHARY C | 1 | 63.9% | +37.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18164521 | INFLAMMATORY CYTOKINES AND FATIGUE IN SUBJECT WITH A COMPLEMENT MEDIATED DISEASE | WEIDNER, ADAM M | 26d overdue |
| 18477981 | REDUCING SURGERY-ASSOCIATED HEMOLYSIS IN COLD AGGLUTININ DISEASE PATIENTS | XIAO, YAN | — |
| 18334567 | ANTI-COMPLEMENT C1S ANTIBODY FORMULATION | KIM, YUNSOO | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17818885 | HUMANIZED ANTI-C1S ANTIBODIES AND METHODS OF USE THEREOF | HOWARD, ZACHARY C | 36d overdue |
| 18164521 | INFLAMMATORY CYTOKINES AND FATIGUE IN SUBJECT WITH A COMPLEMENT MEDIATED DISEASE | WEIDNER, ADAM M | 26d overdue |
| 18477981 | REDUCING SURGERY-ASSOCIATED HEMOLYSIS IN COLD AGGLUTININ DISEASE PATIENTS | XIAO, YAN | — |
| 18334567 | ANTI-COMPLEMENT C1S ANTIBODY FORMULATION | KIM, YUNSOO | — |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| 1644 | 1 |
| 1675 | 1 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18477981 | REDUCING SURGERY-ASSOCIATED HEMOLYSIS IN COLD AGGLUTININ DISEASE PATIENTS | XIAO, YAN | 1642 | §102§103 | Non-Final OA | — | Pending | Sep 29, 2023 |
| 18334567 | ANTI-COMPLEMENT C1S ANTIBODY FORMULATION | KIM, YUNSOO | 1644 | §103§112 | Non-Final OA | — | Pending | Jun 14, 2023 |
| 18164521 | INFLAMMATORY CYTOKINES AND FATIGUE IN SUBJECT WITH A COMPLEMENT MEDIATED DISEASE | WEIDNER, ADAM M | 1675 | §101§103Other | Final Rejection | 26d overdue | Pending | Feb 03, 2023 |
| 17818885 | HUMANIZED ANTI-C1S ANTIBODIES AND METHODS OF USE THEREOF | HOWARD, ZACHARY C | 1674 | Other | Final Rejection | 36d overdue | Pending | Aug 10, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBioverativ Usa Inc. has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Yan Xiao has the most, with 1 of Bioverativ Usa Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
